Seeking Alpha

Questcor Pharmaceuticals (QCOR -6.3%) says the number of paid prescriptions for its primary...

Questcor Pharmaceuticals (QCOR -6.3%) says the number of paid prescriptions for its primary product, Acthar, dipped M/M in February. The result contrasts with the general pattern of explosive growth for Acthar, as QCOR has quickly built up its salesforce to promote the drug used to treat multiple sclerosis and other diseases.
Comments (3)
  • Ernest P Icahn
    , contributor
    Comments (377) | Send Message
     
    Insiders sold by the droves in 2011. Maybe they're not the only ones who saw the top of $45.95 at a PE of 56 as too high. Short interest increased. Momentum traders evacuated. Short interest & profit takers prevail. Growth stymied. What would you expect other than a falling stock? -Ernest
    11 Mar 2012, 12:54 PM Reply Like
  • nyuboy1
    , contributor
    Comment (1) | Send Message
     
    Insiders should give the stock another look. Acthar gel is the ONLY drug that works to relieve epilepsy in infants. QCOR can charge whatever they want and they DO!! Profits are up and up and the fact they filled 4 less prescriptions this month does not change the fact they are going to come out making 150% EPS gains quarter after quarter.
    13 Mar 2012, 11:30 AM Reply Like
  • Ernest P Icahn
    , contributor
    Comments (377) | Send Message
     
    Oy! I sure hope you don't mean 150% Q after Q Sequentially. lol -Ernest
    14 Mar 2012, 10:07 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|